Not Yet RecruitingNot Applicable

Electroacupuncture for the Treatment of Agitated Symptoms of Alzheimer's Disease

China224 participantsStarted 2024-07-20

Plain-language summary

The purpose of this study is to evaluate the efficacy of electroacupuncture in the treatment of agitation symptoms in patients with Alzheimer's disease (AD). Meanwhile the study aims to explore the brain central mechanism of electroacupuncture in the treatment of agitation symptoms in patients with AD by using resting state functional magnetic resonance technology.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Meet the revised draft diagnostic criteria for Alzheimer's disease published by the Alzheimer's Association in 2023
✓. Meet the 2023 IPA definition of agitated symptoms of cognitive impairment
✓. Cohen Mansfield Agitation Inventory (CMAI)≥45 points
✓. Have been on stable anti-AD medication (cholinesterase inhibitors, etc.) for more than 1 month
✓. If taking antipsychotics, the medication regimen for agitation (antipsychotics) is stable for 1 month prior to randomization
✓. Subject and legal guardian and caregiver sign informed consent.

Exclusion criteria

✕. There are contraindications for acupuncture treatment, such as the tendency of acupoint bleeding or allergy to metal
✕. Received electroacupuncture treatment in the past 2 weeks
✕. At the time of the screening, participants are participating in other clinical trials or planned to participate in other clinical trials in the next 17 weeks.

What they're measuring

Cohen Mansfield Agitation Inventory (CMAI)

Timeframe: CMAI will be evaluated after the final treatment at week 8

Trial details

NCT IDNCT06495957

SponsorGuang'anmen Hospital of China Academy of Chinese Medical Sciences

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-07-31

Contact for this trial

Baohui Jia

010-88001454 jiabaohui2504@gamyy.cn

View on ClinicalTrials.gov More Agitation Associated With Alzheimer's Dementia trials